Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.54 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495556 | 0.90 | USP30 (0.47) | SCN9AUSP30GRM5 | |
| SCHEMBL2493404 | 0.84 | SCN9A (0.44) | SCN9AUSP30GRM5 | |
| SCHEMBL1883650 | 0.83 | SCN9A (0.58) | SCN9ASCN10AGRM5CYP2C9CTSA | |
| SCHEMBL2500100 | 0.83 | USP30 (0.46) | USP30 | |
| SCHEMBL2501040 | 0.83 | SCN9A (0.57) | SCN9ASCN10AGRM5CYP2C9 | |
| SCHEMBL2498107 | 0.83 | USP30 (0.42) | SCN9ASCN10AUSP30CTSA | |
| SCHEMBL2503104 | 0.82 | GSK3B (0.42) | SCN9AUSP30 | |
| SCHEMBL1883803 | 0.82 | SCN9A (0.65) | SCN9ASCN10AGRM5CYP2C9CTSA | |
| SCHEMBL2498110 | 0.81 | SCN9A (0.52) | SCN9ASCN10AGRM5CYP2C9 | |
| SCHEMBL2497672 | 0.81 | SCN9A (0.52) | SCN9ASCN10AGRM5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | claimed |
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | disclosed |
| EP-1937649-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042546-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | GABBR1, GABRB2, GABRB3 | SCN9A 1508/4885SCN10A 1149/4885USP30 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.